#876: Dr. Andrew Huberman — Peptides, Performance, and Protocols

What It Covers

Tim Ferriss and Stanford neuroscientist Andrew Huberman cover Huberman's current 6-day training split informed by training sessions with 6-time Mr. Olympia Dorian Yates, personal experiences with MDMA and psilocybin in clinical settings, the peptide landscape including BPC-157 and GLP agonists, cortisol bookending for sleep optimization, and neuroplasticity principles underlying all health interventions.

Key Questions Answered

• •Dorian Yates Training Split: Huberman runs a 3-day resistance training split — legs, then chest/back/neck, then shoulders/arms — with 2 working sets per exercise taken to failure, plus 3 cardio sessions weekly. Each muscle group gets direct stimulus once and indirect stimulus a second time via cardio. This structure resolves the collision between hypertrophy volume recommendations (10–20 sets/week) and concurrent cardio demands that most peer-reviewed studies ignore entirely.
• •Cortisol Bookending for Sleep: Morning bright light exposure increases the cortisol awakening response by approximately 50%, and stacking it with cold exposure, caffeine, and exercise further amplifies the peak. A high morning cortisol spike ensures a low evening baseline, which enables melatonin rise and quality sleep. The actionable principle: maximize cortisol in the morning through any available means, then protect the evening from cortisol-spiking inputs like late caffeine or high-stress content.
• •Psychedelic Combination Protocol: Huberman describes a clinically supervised protocol combining MDMA followed by high-dose psilocybin (4–5 grams dried mushrooms) in the same session. The MDMA's empathogenic effect — simultaneously raising dopamine, serotonin, and oxytocin — provided psychological stability to endure the difficult psilocybin experience. Critically, this combination eliminated the typical 2-day post-MDMA energy drop. He emphasizes the 2–3 weeks following any psychedelic session as a neuroplasticity window requiring directed behavioral work.
• •Peptide Categories and Risk Tiers: Huberman organizes peptides into four practical categories: GLP agonists for weight loss (tirzepatide, semaglutide), growth hormone secretagogues (sermorelin, tesamorelin, CJC), tissue repair compounds (BPC-157, TB-500), and miscellaneous neuroactive peptides (epithalon, pinealon). His risk-adjusted recommendation: only use BPC-157 for active injuries sourced from compounding pharmacies like TaylorMade or Upstate, not as a general recovery supplement. Gray-market sourcing carries contamination risk from lipopolysaccharides.
• •Pinealon for REM Sleep: Pinealon, a peptide derived from the neocortex (not the pineal gland despite its name), produces a measurable increase in REM sleep — Huberman reports reaching 3 hours of REM in a single night without disrupting slow-wave sleep. The effect carries over into subsequent nights. Alpha-GPC at 900mg serves as a non-prescription alternative that also increases REM and allows late-day workouts without caffeine-related sleep disruption. Both tools are for occasional use, not daily supplementation.
• •Neuroplasticity Requires Directed Action: Increasing BDNF through exercise, or opening plasticity windows through psychedelics or TMS, does not automatically rewire the brain. Coordinated pre- and post-synaptic neural firing toward a specific skill or behavioral target is required. Huberman references accelerated TMS protocols enhanced by D-cycloserine (125mg oral, taken 1 hour before stimulation), which compressed a 5-day treatment into a single day and produced a 90% reduction in his generalized anxiety and OCD symptoms lasting 3–4 months per session.
• •Sermorelin PSA Warning: Huberman tried sermorelin, a growth hormone secretagogue, and observed a spike in prostate-specific antigen (PSA) with no mechanistic explanation from clinicians. PSA normalized after discontinuation. The compound also eliminated REM sleep while increasing slow-wave sleep. His conclusion: for those who want growth hormone benefits, 1–2 IUs of pharmaceutical-grade somatotropin (omnitrope) taken 5 nights per week produces superior outcomes — better deep sleep, tissue repair, and cognitive function — with a cleaner risk profile than gray-market secretagogues.